Poseida Therapeutics shares are trading higher after the company received Regenerative Medicine Advanced Therapy designation from the FDA for P-BCMA-ALLO1 in relapsed/refractory multiple myeloma.
Portfolio Pulse from Benzinga Newsdesk
Poseida Therapeutics shares rose after receiving FDA's Regenerative Medicine Advanced Therapy designation for P-BCMA-ALLO1, a treatment for relapsed/refractory multiple myeloma.
September 16, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Poseida Therapeutics received a significant regulatory boost as the FDA granted Regenerative Medicine Advanced Therapy designation for its P-BCMA-ALLO1 treatment, leading to a rise in share prices.
The FDA's designation is a positive regulatory development, likely to enhance investor confidence and increase the perceived value of Poseida's pipeline, thus driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100